Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service decompression & minimally invasive spine cases in Idaho: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (250 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 26 | 946 | 37% |
| 2020 | 24 | 930 | 40% |
| 2021 | 22 | 943 | 43% |
| 2022 | 17 | 818 | 47% |
| 2023 | 23 | 859 | 50% |
| 2024 | 23 | 876 | 52% |
| 2025 from claims | – | 892 721–1,047 | 54% |
| 2026 forecast | – | 998 782–1,253 | 49% |
| 2027 forecast | – | 1,029 763–1,360 | 49% |
| 2028 forecast | – | 1,060 751–1,464 | 49% |
| 2029 forecast | – | 1,093 743–1,567 | 49% |
| 2030 forecast | – | 1,127 738–1,672 | 48% |
Laminotomy, laminectomy, interspinous devices; the MIS call point. Professional codes (what the surgeon bills): CPT 63030, 63047, 63020, 63045, 22867; the hospital bills MS-DRG 518, 519, 520.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 66% of the cases CMS names in Idaho; 15 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 41% inpatient hospital, 58% hospital outpatient, 1% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 219 | 9,586−3.4%/yr | −3.4%/yr | 2.8 | 7% | 10,100 in 2030+0.8%/yr |
| Arizona | 72 | 2,815−4.4%/yr | −4.4%/yr | 3.7 | 14% | 3,290 in 2030+2.6%/yr |
| Washington | 74 | 2,603−5.2%/yr | −5.2%/yr | 3.3 | 17% | 2,650 in 2030+0.3%/yr |
| Colorado | 51 | 2,105−5.5%/yr | −5.5%/yr | 4.2 | 5% | 2,480 in 2030+2.7%/yr |
| Oregon | 37 | 1,683−5.9%/yr | −5.9%/yr | 3.9 | 38% | 1,690 in 20300%/yr |
| Utah | 31 | 1,279−3.9%/yr | −3.9%/yr | 5.6 | 16% | 1,510 in 2030+2.8%/yr |
| Nevada | 27 | 1,021−8%/yr | −8%/yr | 3.4 | 4% | 1,050 in 2030+0.5%/yr |
| Montana | 11 | 616−3.5%/yr | −3.5%/yr | 3.2 | 9% | 590 in 2030−0.8%/yr |
| Alaska | 10 | 340+0.8%/yr | +0.8%/yr | 2.8 | 13% | 430 in 2030+3.8%/yr |
| Wyoming | 9 | 331−4.1%/yr | −4.1%/yr | 3.0 | 10% | 310 in 2030−0.8%/yr |
| New Mexico | 7 | 250−13%/yr | −13%/yr | 1.0 | 0% | 350 in 2030+5.7%/yr |
| Hawaii | 7 | 234−1.1%/yr | −1.1%/yr | 1.8 | 12% | 140 in 2030−8.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Lumbar fusion | 21 | 882+2.3%/yr | +2.3%/yr | 4.21.5× | 2% | 1,290 in 2030+6.6%/yr |
| Cervical fusion & disc arthroplasty | 8 | 341−3.9%/yr | −3.9%/yr | 1.61.3× | 0% | 450 in 2030+4.8%/yr |
| Kyphoplasty & vertebroplasty | 3 | 261−4.7%/yr | −4.7%/yr | 1.31.4× | 0% | 490 in 2030+11%/yr |
| SI joint fusion | 2 | 102+43%/yr | +43%/yr | 0.52.1× | 0% | 170 in 2030+8.4%/yr |
Decompression & minimally invasive spine in every state, and its device makers · Every procedure market in Idaho · Every state · Compare with California
Globus Medical leads with 62% of company spending on these surgeons in 2025, +61 pts on 2024.
In 2025, 5 companies reported engagement with Idaho’s surgeons worth $189K in consulting, speaking, meals and travel tied to these products, about $8,209 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.